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B cells are important in the development of autoimmune disorders through mechanisms involving
dysregulated polyclonal B-cell activation, production of pathogenic antibodies, and targeting which re-
duces inﬂammation and tissue damage effectively but often leads to patients suffering from secondary
infection. Paeoniﬂorin (PF) is the main substance of the Total glucosides of peony and has been widely
used to treat autoimmune diseases for years. However, whether PF affects B cell activity remains un-
known. In this study, using puriﬁed murine spleen B cells, we analyzed the effects of PF on B-cell function
in vitro. We found that PF inhibited the expression of CD69/CD86 and the proliferation of B cells stim-
ulated by LPS. In addition, PF reduced the B-cell differentiation and immunoglobulin production that was
stimulated by LPS. Interestingly, PF did not alter B-cell activation and proliferation provoked by anti-
CD40 or IL-4. These results indicated for the ﬁrst time that PF inhibits B-cell activation, proliferation
and differentiation by selectively blocking the LPS/TLR4 signaling pathway. Furthermore, our data sug-
gest that PF selectively inhibits inﬂammation and tissue damage mediated by LPS-activated B cells but
does not alter CD40/CD40L- or IL-4-provoked B-cell function in autoimmune diseases treatment, which
might aid in protecting patients from secondary infection.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
As a unique cell type in the immune system, B lymphocytes are
the principal components of the adaptive immune system, but also
serve various innate immune functions that play an important role
in protective immunity as producers of both antibodies and cyto-
kines (1, 2). It is well known that B-cell receptor (BCR), CD40/CD40
ligand (CD40L), IL-4 and lipopolysaccharide (LPS) signaling are
involved in B-cell activation (3, 4). The CD40/CD40L signaling
promotes B cell proliferation and cytokines production (5, 6). IL-4
mediates B-cell activation and proliferation by enhancing the an-
tigen presentation of B cells (7). Thus, CD40/CD40L and IL-4
signaling are indispensible in T-cell-dependent B cell activation
and play a critical role in adaptive immunity. LPS is ligand of TLR4munology & Department of
niversity School of Medicine
hina. Tel.: þ86 21 64453149;
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).and is expressed on the membrane of many cells, including B cells
(8). LPS/TLR4 can stimulates B cell activation, leading to pro-
inﬂammatory cytokine production (9), induction of class switch
recombination in innate and adaptive immune responses (10).
Through presenting auto-antigens and producing auto-
antibodies, B cells are involved in the pathogenesis of autoim-
mune diseases. The role of B cells in the pathogenesis of rheuma-
toid arthritis (RA) (11), type I diabetes (12), systemic lupus
erythematosus (SLE) (13), and several other autoimmune inﬂam-
matory diseases has been described fully. Auto-reactive B cells can
present self-antigens to auto-reactive T cells, produce auto-
antibodies and pro-inﬂammatory cytokines, such as TNF-a and
interleukin-6 (IL-6), in autoimmune diseases (14). Autoantibodies
can greatly amplify inﬂammatory responses and promote tissue
damage. Immune complexes containing IgM or IgG autoantibodies
can initiate complement-mediated inﬂammation and promote
antibody-dependent cellular cytotoxicity by NK cells or macro-
phages (15e17). Thus, inhibiting the abnormal activation of B cells
is required for therapeutic efﬁcacy in patients with autoimmune
diseases; however, maintaining the normal function of B cells as far
as possible should be considered for preventing the occurrence of
secondary infection in the treatment of autoimmune diseases.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Paeonia lactiﬂora pall (18, 19). Paeoniﬂorin (PF) is the main active
substance of TGP for treatment of autoimmune diseases, e.g., RA,
SLE, Diabetic nephropathy (DN) and Sjogren's Syndrome (SS) etc.,
for many years (20). Mechanismly, PF has been shown to affect anti-
inﬂammatory and immune-regulatory functions by attenuating the
functional maturation of dendritic cells (21), inhibiting Th1/Th17
cells development in RA patients (22), altering the methylation of
regulatory T cells (Treg) of SLE patients (23), and up-regulating the
Treg population in an animal model of SS (24e26). Moreover, PF
was reported to be signiﬁcantly efﬁcient in decreasing the anti-SSA/
SSB produced in experimental SS mice, suggesting that PF possibly
altered B cells function in vivo. However, whether and how PF affect
the activities of B cells remains unclear.
In this study, we analyzed the effects of PF on activities of mu-
rine B cells in vitro. We stimulated B cells with LPS, anti-CD40 and
IL-4 in the presence of different concentrations of PF. The results
showed that LPS, anti-CD40 and IL-4 provoked B cell activation,
which was characterized by higher expression levels of molecules
such as CD69 and CD86 and a signiﬁcant increase in proliferation.
However, we found that PF could inhibit CD69 and CD86 expression
and the B cell proliferation stimulated by LPS, but did not alter the B
cell activation and proliferation provoked by anti-CD40 and IL-4.
Furthermore, we found that PF reduced the formation of
antibody-secreting cells (B220lowCD138þ B cells) derived from B
cells activated by LPS; consistently, PF impaired the immunoglob-
ulin production (IgM, IgG1, IgG2a, IgG2b and IgG3) of B cells
stimulated by LPS. Our study indicates for the ﬁrst time that PF
inhibits B-cell activation and proliferation by blocking the LPS/TLR4
signaling pathway selectively, suggesting that PF provides an
advantage for autoimmune disease treatment but does not alter
CD40/CD40L- and IL-4-provoked B-cell function.
2. Material and methods
2.1. Animals
Female C57BL/6J mice, 6e8 weeks of age, were purchased from
the Shanghai Laboratory Animal Center, Chinese Academy of Sci-
ence and were kept under pathogen-free conditions at the animal
core facility of Shanghai Jiao Tong University School of Medicine. All
experiments were performed according to the Animal Care and Use
Committee guidelines.
2.2. B cell puriﬁcation
To obtain puriﬁed murine B cells, spleens from naïve mice were
removed and freshly prepared for single-cell suspensions by
mincing through cell strainers, and the erythrocytes were lysed
with an ammonium chloride solution. B cells were negatively iso-
lated from the resulting splenocytes using magnetic bead separa-
tion. Brieﬂy, splenocytes were depleted for T cells, monocytes/
macrophages, dendritic cells, NK-cells, granulocytes, platelets, and
CD43-positive B cells (activated B cells, plasma cells, CD5þ B1a
cells) using biotin-labeled speciﬁc mAb and anti-biotin magnetic
beads (Invitrogen Life Technologies, Gaithersburg, MD) and an LD
magnetic bead column (MiltenyiBiotec, Auburn, CA, USA). The pu-
rity of the isolated cells was veriﬁed by ﬂow cytometric analysis;
the percentage of B220þ cells was approximately 95%.
2.3. B-cell culture
Puriﬁed resting B cells were cultured in complete RPMI-1640
medium (Gibco, New York, USA) containing 10% heat-inactivated
fetal bovine serum (FBS; Gibco), 100 mg/ml streptomycin (Gibco),100 units/ml penicillin and 2 mM L-glutamine (Gibco). B cells were
seeded at 1e5 105 cells/well in a ﬁnal volume of 200 ml in 96-well
ﬂat-bottom plates (for proliferation and activation assay) or
1  107cell/well in a ﬁnal volume of 1 ml in 24-well plates (for
antibody-secreting cell transformation and immunoglobulin pro-
duction assay).
2.4. B cell stimulation
LPS was purchased from SigmaeAldrich (St. Louis, MO). Anti-
mouse CD40 mAb (clone HM-40.3) was obtained from BD Phar-
mingen (San Diego, CA). Mouse IL-4 was purchased from PeproTech
(Rocky Hill, NJ). Puriﬁed murine B cells were stimulated with LPS
(1 mg/ml), anti-mouse CD40mAb (50 ng/ml) andmouse IL-4 (10 ng/
ml).
2.5. Drugs
PF was supplied from Liwah Plant Extraction Technology Co.,
Ltd. (Ningbo, China) (21). The molecular weight of PF is 480.05. PF
was dissolved in double-distilled water and ﬁltered. In this study,
1 mg/ml, 10 mg/ml, 100 mg/ml and 500 mg/ml of PF were added into
cultured and stimulated B cells to analyze the inhibiting titration of
PF in vitro.
2.6. Flow cytometry analysis
Cells were washed with PBS containing 2 mM EDTA and then
stained with various ﬂuorochromes using standard methods pro-
vided by the manufacturers. Antibodies used for surface staining of
FITC-labeled anti-mouse CD86, PE-labeled anti-mouse CD69, and
APC-labeled anti-mouse B220 Abs were purchased from e-Biosci-
ence. For the detection of antibody-secreting cells, cultured cells
were incubated with APC-labeled anti-mouse B220 and PE-Cy7-
labeled anti-mouse CD138 (e-Bioscience, San Diego, CA, USA).
Isotype-matched antibodies were used as controls, and cells were
pre-incubated with anti-Fc receptor (CD16/CD32) Ab 2.4G2 (BD
Pharmingen) to reduce Fc receptor-mediated non-speciﬁc binding.
To examine B cell activation, double-positive signals of B220 and
CD19 (e-Bioscience, San Diego, CA, USA) were used to gate B cells.
All samples were detected using a BD FACS Canto II ﬂow cytometer
(Becton Dickinson, San Jose, CA, USA) and analyzed by FlowJo 7.6.2
software (Treestar Inc., California, USA).
2.7. B cell activation assay
To analyze B-cell activation, puriﬁed murine B cells were stim-
ulated with LPS, anti-mouse CD40 mAb, or IL-4 in presence of
different concentrations of PF. After 24 h, the cells were harvested
and stained with anti-mouse B220, anti-mouse CD19, anti-mouse
CD69 and anti-mouse CD86 monoclonal antibodies (described
above). Then, the labeled cells were examined by ﬂow cytometry.
Activated B cells were evaluated according to the percentage of
B220þCD19þCD69þ or B220þCD19þCD86þ populated as previously
described (27).
2.8. B cell division assay
Puriﬁed B cells were stimulated by LPS, and cell division was
detected using ﬂow cytometry as described previously (3). In brief,
1  107/ml of B cells were washed with PBS and subsequently
labeled with carboxy ﬂuorescein succinimidyl ester (CFSE) and
incubated for 10 min at 37 C. Then, RPMI1640 containing 10% FCS
was added to the labeled cells to stop the reaction. Furthermore, the
cells were washed another twice with PBS, the proﬁle of CFSE-
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assay, 1 mg/ml, 10 mg/ml, 100 mg/ml and 500 mg/ml PF were added to
the B cells stimulated by 1 mg/ml LPS. The altered B cell divisionwas
analyzed similarly.2.9. B-cell proliferation assay
B-cell proliferation was examined using a Cell Counting Kit
(CCK)-8 (Dojindo, Japan) according to manufacturer's instructions.
In brief, 4 105 puriﬁed B cells per well were seeded in ﬂat-bottom
96-well plates and stimulated by LPS (1 mg/ml), anti-mouse CD40
mAb (50 ng/ml) and mouse IL-4 (10 ng/ml) in the presence of
titrated PF. After 72 h, 20 mL of CCK-8 solution was applied per well
and then incubated for another 4 h. The absorbance values of all
wells were then measured at 450 nm in a microplate reader (Bio-
Rad, USA).2.10. Antibody-secreting cell transformation assay
To explore the antibody-secreting cell transformation of B cells
upon LPS stimulation in the presence of PF, terminal-differentiated
plasma cells were examined as previously reported (28). Brieﬂy,
4  105 puriﬁed murine B cells were seeded per well in ﬂat-bottom
96-well plates and stimulated by 1 mg/ml of LPS for 72 h in presence
of different doses of PF. Then, the cells were harvested and stained
with PE-Cy7-labeled anti-mouse CD138 and APC-labeled anti-
mouse B220 antibodies and detected by ﬂow cytometry. The
percent of B220lowCD138þ cells (antibody-secreting cells, also
called plasma cells) represented the transformation ability of B cells
induced by LPS in vitro.2.11. Immunoglobulin measurement
B cells were co-cultured with 1 mg/ml LPS in the presence of
1 mg/ml, 10 mg/ml, 100 mg/ml and 500 mg/ml of PF for 72 h (for IgM
production assay) or 96 h (for IgG secretion assay). In brief, su-
pernatants of treated cells were collected for immunoglobulin
production assay. The concentrations of IgM, IgG1, IgG2a, IgG2b,
IgG3 were measured using the SBA Clonotyping System-HRP
(Southern Biotechnology Associates, Birmingham, AL) according
to the manufacturer's recommendations. The effects of PF on
immunoglobulin production capacity of LPS-treated B cells were
evaluated by calculating the decrease in immunoglobulin
concentration.Fig. 1. No effect of PF on B-cell activation and viability. Puriﬁed splenic B cells were
incubated with PF at different concentrations. (A) After 24 h, B cells were stained with
anti-B220/CD45R, anti-CD69, anti-CD86 antibodies, and CD69þ B cells (open bar) and
CD86þ B cells (black bar) were analyzed by ﬂow cytometry. (B) After a 72 h incubation,
B cells in the control group were treated with control medium (open bar), B cells in the
positive control group were cultured with 1 mg/ml LPS (black bar), and B cells in the
testing group were incubated with 1e500 mg/ml PF (shadow bar). B-cell viability was
assessed as the absorbance of OD450 nm using a CCK assay kit. The data represent
three independent experiments.2.12. Western blot analysis
Protein immune blotting was performed as described previously
(3). In brief, puriﬁed mouse B cells (1  107cell/ml/well) were
stimulated by LPS in the presence of 100 mg/ml PF for 5 and 15 min.
Then, the cells were harvested and subsequently lysed in ice-cold
lysis buffer (50 mM TriseHCl, pH 7.4, 1% Nonidet P-40, 137.5 mM
NaCl, 1% glycerol, 1 mM sodium orthovanadate, and 0.5 mM EDTA,
pH 8.0). After centrifugation, the lysates were resolved by 10% SDS-
PAGE and electro-blotted to a 0.2-mm polyvinylidenediﬂuoride
membrane (Millipore) at 250 mA for 1 h. The blots were blocked in
5% milk, washed with PBST, and incubated with primary Abs.
AntieNFeкB (P65), anti-phosphoeNFeкB (p-P65), anti-ERK1/2,
anti-phospho-ERK1/2 Abs were purchased from Cell Signaling
Technology (Beverly, MA). After incubation with HRP-conjugated
goat anti-rabbit at room temperature for 1 h followed by washing
with PBST, the bound Igs were detected using ECL system (Bio Rad)
and visualized by autoradiography.2.13. Statistical analyses
Reported values are expressed as mean ± SEM. Data shown are
representative of three independent replicates. All statistical ana-
lyses were performed using PRISM software (GraphPad Software,
La Jolla, CA). For all studies, statistical significance was assessed
using one-way analysis of variance followed by a Dunnett's post-
test (for statistical significance between experimental groups and
control group). Control groups are B cells stimulated by LPS/anti-
CD40/IL-4 only, however, experimental groups are B cells treated
by both LPS/anti-CD40/IL-4 and different doses of PF. Significance
was set at a P-value of 0.05.3. Results
3.1. No effect of PF on B cell activation and viability
To determine the treatment concentrations of PF at a range with
no apparent cytotoxicity, B cells were incubated with 1e500 mg/ml
PF, and the effect on cell activation and viability were assessed. The
expression of CD69 and CD86, two representative markers for B-
cell activation examined 24 h after incubation, was not altered at
the tested concentrations (Fig. 1A). In addition, B cells, after expo-
sure to PF for 72 h, were submitted to the CCK-8 Cell Counting
Detection assay for cell viability measurement. The results showed
that B cells were viable after exposure to PF even at the maximum
PF concentration (Fig. 1B). Therefore, we used 500 mg/ml as the
highest concentration in following experiments.
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To address PF effects on puriﬁed B cell activation stimulated by
LPS, we analyzed the proﬁle of LPS-inducing CD69 and CD86
expression on B cells in the presence of PF. The results showed that
PF, from 10 mg/ml to 500 mg/ml, demonstrated a dose-dependent
inhibitory effect on CD69 and CD86 expression in B cells under
LPS stimulation (Fig. 2A). Nevertheless, analysis shown that 1 mg/ml
or 10 mg/ml of PF did not signiﬁcantly alter either CD69 or CD86
expression; 100 mg/ml of PF attenuated the expression of CD69 and
CD86 on B cells efﬁciently, while 500 mg/ml of PF signiﬁcantly
reduced the expression of CD69 and CD86 on B cells (Fig. 2B). Thus,
PF signiﬁcantly inhibited B cell activation stimulated by LPS in vitro,
indicating that PF decreases LPS-induced B-cell activation in a dose-
dependent manner.
3.3. PF suppressed B-cell proliferation and division
Next, we questioned whether PF could suppress B-cell prolif-
eration and division in vitro. First, using CCK-8 Cell Counting
Detection Kit, we examined the proliferation of B cells stimulated
by LPS and found that 1 mg/ml of LPS could provoke B-cell prolif-
eration signiﬁcantly. However, the LPS-induced B cell proliferation
was inhibited by PF (Fig. 3A). Further analysis showed that 100 mg/
ml PF reduced LPS-induced B-cell proliferation signiﬁcantly
(p < 0.01), while 500 mg/ml PF displayed a stronger inhibition
(p < 0.001; Fig. 3A), indicating that PF down-regulated LPS-stim-
ulated B-cell proliferation in a dose-dependent manner. Moreover,
we explored whether PF altered the proﬁle of B-cell division
induced by LPS. The results showed that, compared with the B cells
stimulated with LPS alone, 1 mg/ml and 10 mg/ml of PF did not
reduce passages of B-cell stimulated by LPS signiﬁcantly. However,
the passages of B cells were remarkably decreased in the presenceFig. 2. PF effects on B cell activation stimulated by LPS. LPS (1 mg/ml) was used to stimulate
anti-B220/CD45R, anti-CD69, and anti-CD86 antibodies and examined by ﬂow cytometry. (A
The mean ﬂuorescent intensity of CD69þ and CD86þ in B220þ B cells are shown, with an evid
2 independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).of 100 mg/ml PF, with a nearly 90% decrease by 500 mg/ml PF
(Fig. 3B), indicating that PF inhibits B-cell proliferation and division
stimulated by LPS in vitro in a dose-dependent manner.
3.4. PF altered B cell differentiation into antibody-secreting cells
It is well known that activated B cells differentiate into
antibody-secreting/plasma cells terminally, leading to adaptive
immune response in vivo. Thus, analyzing the alterations in the
population of plasma cells is used to evaluate the function of
induced B cells in vitro. Given that higher CD138 but lower B220
levels are found on antibody-secreting cells, quantiﬁed CD138þ
cells in the B220low population is widely used to assess antibody-
producing cell formation (29). Based on the results that PF inhibi-
ted LPS-induced B cell activation and proliferation, we examined
whether PF affected antibody-secreting cells differentiated from
LPS-treated B cells. We stimulated B cells with LPS for 72 h and
compared the formation of plasma cells with or without PF treat-
ment. Accordingly, we quantiﬁed CD138þ cells in the B220low
population (Supplementary Fig. 1) and found that LPS signiﬁcantly
stimulated the generation of B220lowCD138þ plasma cells (Fig. 4A).
While 100 mg/ml and 500 mg/ml of PF signiﬁcantly reduced the
formation of antibody-secreting cells respectively (Fig. 4B), indi-
cating that PF efﬁciently reduced the formation of plasma cells
stimulated by LPS in vitro in a dose-dependent manner.
3.5. PF attenuated immunoglobulin produced by antibody-secreting
cells derived from LPS-activated B cells
Given that plasma cells produce auto-antibodies and are
involved in the pathogenesis of autoimmune diseases (30, 31), we
examined the effects of PF on immunoglobulins produced by
transformed plasma cells in vitro. It is well known that, in thepuriﬁed B cells in the presence or absence of PF. After 24 h, the cells were stained with
) Expression of CD69 and CD86 in B220/CD45Rþ cells is displayed with line charts. (B)
ent dose-dependent pattern. The data are expressed as the mean ± SEM of triplicates of
Fig. 3. PF inhibited B-cell proliferation and division stimulated by LPS. Puriﬁed splenic B cells were stimulated by LPS with the indicated concentrations in the presence (shadow
bar) or absence (black bar) of increasing concentrations of PF compared with negative control (open bar). (A) After 72 h, proliferation was evaluated using a Cell Counting Detection
Kit. (B) After 96 h, CFSE-stained cells were collected for cell division assay by ﬂow cytometry. The data are expressed as the mean ± SEM of triplicates of 2 independent experiments
(**P < 0.01, ***P < 0.001).
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IgM ﬁrst and then generate IgG. Accordingly, we tested IgM
secretion by antibody-producing cells derived from LPS-treated B
cells. The results showed that PF could inhibit IgM production with
a dose-dependent manner (Fig. 5A). Furthermore, we examined IgG
production by plasma cells derived from LPS-treated B cells andFig. 4. CD138 expression in B220-enriched B-cell population activated by LPS in association w
After 72 h, the population was enriched for CD138-positive cells as described in the Materia
CD138 antibodies, and the expression of these molecules was determined by ﬂow cytomet
CD138þ plasma cells derived from B cells stimulated by LPS in the presence (shadow bar) or
expressed as the mean ± SEM of triplicates of 2 independent experiments (*P < 0.05, **P <found that PF reduced IgG production in a dose-dependent
manner; the concentrations of all isotypes of IgG (IgG1, IgG2a,
IgG2b and IgG3) were decreased signiﬁcantly (Fig. 5B) in vitro.
These results indicated that PF not only reduced the formation of
antibody-secreting cells, but also suppressed antibody production
in vitro.ith PF. Puriﬁed B cells were cultured with 1 mg/ml LPS in the presence or absence of PF.
ls and Methods section. B220-enriched puriﬁed B cells were then co-stained with anti-
ry. (A) The proportion of B220lowCD138þ plasma cells. (B) The percentage of B220low-
absence (black bar) of PF compared with the negative control (open bar). The data are
0.01).
Fig. 5. PF altered the immunoglobulin secretion of B cells stimulated by LPS in vitro. Puriﬁed B cells were cultured with 1 mg/ml LPS in the presence or absence of PF. The cell culture
supernatants were collected and measured by ELISA. (A) The level of IgM produced by LPS-stimulated B cells at 72 h. (B) The concentration of different isotypes of IgG produced by
LPS-stimulated B cells at 96 h. The data are expressed as the mean ± SEM of triplicates of 2 independent experiments (*P < 0.05, ***P < 0.001).
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NF-kB/ERK signaling pathways
Previous studies have identiﬁed that NF-кB and ERK signaling
pathways link to LPS-induced B-cell activation (32). We therefore
examined alterations in NF-kB/ERK phosphorylation of LPS-induced
B cells treated with PF. We added 1 mg/ml LPS into the B cells co-
cultured with 100 mg/ml of PF or not and subsequently incubated
for 5 and 15 min. Then, we collected the cells and examined the
proﬁle of NF-kB and ERK phosphorylation at 5 min and 15 min. The
results showed that p-p65 and p-ERK of B cells stimulated with LPS
alone were enhanced signiﬁcantly, however, when LPS-induced B
cells were treated with 100 mg/ml of PF for 15 min, the expression of
p-p65 and p-ERK was inhibited dramatically compared with the
cells without PF treatment (Fig. 6), repeated experiments showed
the consistent results (Supplementary Fig. 2). These results sug-
gested that both NF-kB and ERK phosphorylation of LPS-provoked B
cells were affected by PF simultaneously, which is consistent with
our previous reports.
3.7. PF did not alter B-cell activation and proliferation induced by
an anti-CD40 antibody and IL-4 in vitro
It is well known that LPS/TLR4, B-cell receptor (BCR) or CD40/
CD40L and IL-4 signaling pathways play different roles in B-cellFig. 6. Signaling pathways involved in PF alleviated B cell function stimulated by LPS. Puriﬁe
LPS in the presence or absence of 100 mg/ml PF for 5 min and 15 min. The proﬁle of NF-kB an
mean ± SEM of 3 independent experiments (*P < 0.05, **P < 0.01).activation and antibody production: LPS enhances activation, in-
ﬂammatory cytokine production and IgG2b class switch of B cells;
anti-CD40 induces antigen-presenting, early activation and prolif-
eration of B cells; and IL-4 is involved in B-cell activation and
functional mutation (7, 10, 33, 34). Given that we had obtained
evidence for PF inhibition of B-cell activation and proliferation
provoked by LPS, we explored whether PF affected B-cell activation
and proliferation induced by the CD40/CD40L and IL-4 signaling
pathways. We added an anti-mouse CD40 monoclonal antibody
and a mouse IL-4 as agonists to puriﬁed murine B cells and
examined B-cell activation and proliferation. The results showed
that when B cells were incubated with anti-mouse CD40 mono-
clonal antibody for 24 h, the mean ﬂuorescent intensity of CD69þ B
cells was increased more than 3 times, a signiﬁcant increase;
however, the mean ﬂuorescent intensity of CD86þ B cells increased
no more than twice (Fig. 7A). In contrast, when B cells were treated
with mouse IL-4, CD86 was signiﬁcantly increased on B cells; the
mean ﬂuorescent intensity of CD86þ B cells increased more than 4
times, but CD69 displayed a lower increase of no more than twice
(Fig. 7C). These data indicate that PF does not affect the proﬁle of
CD69 and CD86 expression stimulated by the CD40/CD40L or IL-4
signaling pathways (Fig. 7A and B). Consistently, in the prolifera-
tion assay, we found that PF did not inhibit B cell proliferation
induced by anti-mouse CD40 monoclonal antibody (Fig. 7C) or
mouse IL-4 (Fig. 7D) for 72 h. It indicated that PF inhibits neither Bd mouse splenic B cells (1  107cell/well in 24-well plate) were stimulated with 1 mg/ml
d ERK phosphorylation was analyzed by immunoblotting. The data are expressed as the
Fig. 7. PF effects on B-cell activation and proliferation provoked by anti-CD40 mAb and IL-4. Puriﬁed mouse splenic B cells were stimulated with anti-CD40 mAb and IL-4 in the
presence or absence of titrated concentrations of PF. Expression of CD69 and CD86 was detected by ﬂow cytometry after 24 h to evaluate B-cell activation. A Cell Counting Kit (CCK-
8) was used to detect cell proliferation after 72 h. (A) The mean ﬂuorescent intensity of CD69þ B cells (open bar) and CD86þ B cells (black bar) stimulated by anti-CD40 mAb. (B) The
mean ﬂuorescent intensity of CD69þ B cells (open bar) and CD86þ B cells (black bar) stimulated by IL-4. (C) The OD450 value for the proliferation assay of B cells stimulated by anti-
CD40 mAb in presence (shadow bar) or absence (black bar) of PF. (D) The OD450 value for the proliferation assay of B cells stimulated by IL-4 in presence (shadow bar) or absence
(black bar) of PF. The data are expressed as the mean ± SEM of 3 independent experiments.
J. Zhang et al. / Journal of Pharmacological Sciences 128 (2015) 8e1614cell early activation nor proliferation provoked by CD40/CD40L and
IL-4 signaling pathways.4. Discussion
As an extract from the root of Paeonia lactiﬂora, PF has been
widely used to treat autoimmune diseases (18). In RA patients, PF
ameliorates clinical symptoms, decreases erythrocyte sedimenta-
tion rate (ESR) and the degree of dripping of rheumatoid factor (RF).
Studies of the mechanisms involved have shown that PF can inhibit
the population of Th1 and Th17 cells and reduces the production of
the inﬂammatory cytokines TNF-a and IL-2 in animalmodels. In SLE
patients, PF could increase Treg function (23). PF was also reported
to abrogate DSS-induced colitis via decreasing TLR4 expression and
suppressing the activation of NF-kB and MAPK pathways (35). In
addition, PF was found to decrease anti-SSA/SSB but up-regulate
the Treg population in an experimental animal model of SS (24),
indicating that PF may affect B-cell function in vivo. The dual-
directional regulatory effect of PF involves reducing Th1/Th17
cells, increasing Treg and Th2 cells in inﬂammatory autoimmune
diseases or models (36). Recently, PF was reported as having a
protective effect on the cerebral ischemic rat by activating adeno-
sine A1 receptor (37). The mechanism of how PF inﬂuences the
expression or function of immune-related or non-related mole-
cules is not fully understood, and further studies are clearly
required.
In our current study, we analyzed the effects of PF on activities of
B cells stimulated with LPS, anti-mouse CD40 and mouse IL-4 using
puriﬁed murine spleen B cells. We found that PF only inhibited B-
cell activation and proliferation provoked by LPS but did not alter
the B-cell activation and proliferation provoked by anti-CD40 and
IL-4 signaling pathway in vitro.Normally, CD40 expressed on B-cell membranes combines
with CD40L expressed on Th2 cells to support B-cell activation and
proliferation as a second signal (38). Thus, the interaction of CD40/
CD40L is very important in B-cell activation and proliferation
contributed by B cells in adaptive immunity. Either CD40 or CD40L
deﬁciency reduces the function of B cells, leading to decreased
defense capacity and patient susceptibility to infection. For
example, soluble CD40 (sCD40) can block the CD40/CD40L inter-
action and down-regulate the immune response mediated by B
cells (39). Studies have shown that there is a higher concentration
of sCD40L in the sera of patients with a malignant tumor (40).
Consistently, sCD40L levels were increased in certain autoimmune
diseases patients who were sensitive to secondary infection. In
our study, PF was not found to inhibit the B cell activation and
proliferation induced by anti-CD40, i.e., PF does not affect the
CD40/CD40L interaction. IL-4 plays a critical role in B cells dif-
ferentiation into antibody-secreting plasma cells and provokes
immunoglobulin production and antibody class switch. Reducing
IL-4 impairs B-cell activation and proliferation, leading to
decreased B-cell activities (41). Our results indicate that PF does
not reduce B-cell activation and proliferation induced by IL-4
signaling pathway.
As a TLR4 ligand, LPS induces the formation of TLR4 and MD-2
heterodimer and then provokes B-cell activation and prolifera-
tion. LPS can induce B cells to express co-stimulatorymolecules and
produce pro-inﬂammatory cytokines, leading to inﬂammation and
tissue damage of autoimmune diseases (9). Moreover, LPS induces
IFN-a production of plasma dendritic cells (pDC) (42) and initiates
autoreactive B-cell activation and proliferation, resulting in auto-
antibodies in SLE patients (13). Thus, down regulating the LPS/TLR4
signaling pathway helps ameliorate inﬂammation and tissue
damage in autoimmune diseases. In this study, we found that PF
inhibited LPS-induced B-cell activation and proliferation and
J. Zhang et al. / Journal of Pharmacological Sciences 128 (2015) 8e16 15reduced the formation of antibody-secreting plasma cells differ-
entiated from LPS-induced B cells signiﬁcantly. Furthermore, PF
down regulated the immunoglobulin production (IgM, IgG1, IgG2a,
IgG2b and IgG3) of B cells stimulated by LPS.
It is known that NF-kB and AP-1 are downstream transcription
factors in the LPS/TLR4 signaling pathways (43). Among these
adapter proteins, NF-kB/AP-1 activation is responsible for
enhancing cytokine production, MHC II and co-stimulatory mole-
cule expression, while IRF contributes to IFN-a production (44). In
this study, we determined that PF selectively arrested the activation
of NF-kB and ERK (AP-1 pathway), which led to attenuated B-cell
activation, reduced proliferation, formation of plasma cells and
immunoglobulin production.
Given that the LPS/TLR4, CD40/CD40L and IL-4 signaling path-
ways are important in B cell activation and function, our study
indicates for the ﬁrst time that PF inhibits B-cell activation and
proliferation by blocking LPS/TLR4 signaling pathway selectively,
suggesting that PF does not affect the adaptive immune responses
mediated by CD40/CD40L and IL-4 signaling of B cells. Thus, our
study indicates that PF may aid in the treatment of autoimmune
diseases via selectively inhibiting inﬂammation and tissue damage
mediated by LPS-activated B cells, which will be a potential beneﬁt
to protect the patients from a secondary infection during the
treatment period.Conﬂicts of interest
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